John Q Doyle, President and CEO of Marsh & McLennan Companies, Inc. (NASDAQ:MRSH), filed a Form 4 on September 3, 2026, disclosing a stock option exercise and same-day share sale executed on September 2, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Doyle exercised stock options covering 16,656 shares of Common Stock at an exercise price of $73.195 per share on September 2, 2026.
  • Shares sold: 16,656 shares of Common Stock were disposed of at $188.51 per share on the same date.
  • Remaining ownership: Following the transactions, Doyle directly beneficially owned 116,811.0205 shares of Common Stock.
  • Rule 10b5-1 plan: Both transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Doyle.
  • Options background: The exercised options were granted on February 22, 2017, and vested in four equal annual installments on February 22nd of 2018, 2019, 2020, and 2021, with an expiration date of February 21, 2027.
  • Residual options: Following the exercise, Doyle retained 16,656 stock options (right to buy) with the same $73.195 exercise price, held directly.

Doyle's Option Exercise and Sale at Marsh & McLennan

According to the filing, John Q Doyle, serving as President and CEO of Marsh & McLennan Companies, Inc., reported two transactions in Common Stock on September 2, 2026. The first was a transaction coded "M," reflecting the exercise of 16,656 stock options at a conversion price of $73.195 per share. Immediately following the exercise, Doyle's directly held Common Stock position stood at 133,467.0205 shares, the filing disclosed.

The filing further reported a same-day sale coded "S," in which 16,656 shares were disposed of at a price of $188.51 per share, reducing Doyle's directly held Common Stock position to 116,811.0205 shares. Both transactions were carried out pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person, according to the filing's explanation of responses.

In Table II, the filing reported that the exercised options were originally granted on February 22, 2017, and vested in four equal annual installments on February 22nd of 2018, 2019, 2020, and 2021. The options carry an expiration date of February 21, 2027. After the exercise transaction, 16,656 stock options (right to buy) at $73.195 remain directly held by Doyle, the filing stated. The Form 4 was signed by Tessa Patti as attorney-in-fact on September 3, 2026.

What Was Disclosed

The filing disclosed a Rule 10b5-1 plan-driven exercise of 16,656 stock options at $73.195 and a same-day sale of 16,656 Common Stock shares at $188.51 by Marsh & McLennan's President and CEO, leaving him with 116,811.0205 directly held shares.